Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR

Breast cancer is the cancer with the highest prevalence in women and is the number-one cause of cancer mortality worldwide. Cell transduction is a fundamental process in the development and progression of cancer. Modifications in various cell signalling pathways promote tumour cell proliferation, pr...

Descripción completa

Detalles Bibliográficos
Autores: Ortega, Miguel Ángel, Fraile-Martínez, O., Asúnsolo, Ángel, Buján, J., García-Honduvilla, N., Coca, S.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/219598
Acceso en línea:http://hdl.handle.net/10261/219598
Access Level:acceso abierto
id ES_d2d2ea96f2fabe96eedb5e7408b4e5d9
oai_identifier_str oai:digital.csic.es:10261/219598
network_acronym_str ES
network_name_str España
repository_id_str
spelling Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOROrtega, Miguel ÁngelFraile-Martínez, O.Asúnsolo, ÁngelBuján, J.García-Honduvilla, N.Coca, S.Breast cancer is the cancer with the highest prevalence in women and is the number-one cause of cancer mortality worldwide. Cell transduction is a fundamental process in the development and progression of cancer. Modifications in various cell signalling pathways promote tumour cell proliferation, progression, and survival. The PI3K/Akt/mTOR pathway is an example of that, and it is involved in growth, proliferation, survival, motility, metabolism, and immune response regulation. Activation of this pathway is one of the main causes of cancer cell resistance to antitumour therapies. This makes PI3K/Akt/mTOR signalling a crucial object of study for understanding the development and progression of this disease. Thus, this pathway may have a role as a potential therapeutic target, as well as prognostic and diagnostic value, in patients with breast cancer. Despite the existence of selective PI3K/Akt/mTOR pathway inhibitors and current clinical trials, the cellular mechanisms are not yet known. The present review aims to understand the current state of this important disease and the paths that must be forged.This work was supported by grants from the B2017/BMD-3804 MITIC-CM (Community of Madrid, Spain), cofinanced by the European Development Regional Fund “A Way to Achieve Europe” (ERDF).Hindawi Publishing CorporationComunidad de MadridEuropean CommissionConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2020202020202020info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/219598reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttp://dx.doi.org/10.1155/2020/9258396Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2195982026-05-22T06:33:51Z
dc.title.none.fl_str_mv Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
title Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
spellingShingle Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
Ortega, Miguel Ángel
title_short Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
title_full Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
title_fullStr Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
title_full_unstemmed Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
title_sort Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR
dc.creator.none.fl_str_mv Ortega, Miguel Ángel
Fraile-Martínez, O.
Asúnsolo, Ángel
Buján, J.
García-Honduvilla, N.
Coca, S.
author Ortega, Miguel Ángel
author_facet Ortega, Miguel Ángel
Fraile-Martínez, O.
Asúnsolo, Ángel
Buján, J.
García-Honduvilla, N.
Coca, S.
author_role author
author2 Fraile-Martínez, O.
Asúnsolo, Ángel
Buján, J.
García-Honduvilla, N.
Coca, S.
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Comunidad de Madrid
European Commission
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
description Breast cancer is the cancer with the highest prevalence in women and is the number-one cause of cancer mortality worldwide. Cell transduction is a fundamental process in the development and progression of cancer. Modifications in various cell signalling pathways promote tumour cell proliferation, progression, and survival. The PI3K/Akt/mTOR pathway is an example of that, and it is involved in growth, proliferation, survival, motility, metabolism, and immune response regulation. Activation of this pathway is one of the main causes of cancer cell resistance to antitumour therapies. This makes PI3K/Akt/mTOR signalling a crucial object of study for understanding the development and progression of this disease. Thus, this pathway may have a role as a potential therapeutic target, as well as prognostic and diagnostic value, in patients with breast cancer. Despite the existence of selective PI3K/Akt/mTOR pathway inhibitors and current clinical trials, the cellular mechanisms are not yet known. The present review aims to understand the current state of this important disease and the paths that must be forged.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/219598
url http://hdl.handle.net/10261/219598
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv http://dx.doi.org/10.1155/2020/9258396
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Hindawi Publishing Corporation
publisher.none.fl_str_mv Hindawi Publishing Corporation
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420406834724864
score 15,811543

Similares en LA Referencia